WallStSmart

AbbVie Inc (ABBV)vsWellgistics Health, Inc. Common Stock (WGRX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 447520% more annual revenue ($62.82B vs $14.03M). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

WGRX

Avoid

30

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -14.20
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-55.6%)

Margin of Safety

-55.6%

Fair Value

$146.00

Current Price

$227.23

$81.23 premium

UndervaluedFair: $146.00Overvalued

Intrinsic value data unavailable for WGRX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.3/10
Market CapQuality
$380.57B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
32.2%10/10

Strong operational efficiency at 32.2%

Debt/EquityHealth
-11.0210/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.598/10

Growing faster than its price suggests

Free Cash FlowQuality
$3.56B8/10

Generating 3.6B in free cash flow

WGRX1 strengths · Avg: 10.0/10
Debt/EquityHealth
-1.9110/10

Conservative balance sheet, low leverage

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
105.1x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-46.2%2/10

Earnings declined 46.2%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

WGRX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$9.35M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.

Bull Case : WGRX

The strongest argument for WGRX centers on Debt/Equity.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.

Bear Case : WGRX

The primary concerns for WGRX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

ABBV is growing revenue faster at 12.4% — sustainability is the question.

ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABBV scores higher overall (63/100 vs 30/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Wellgistics Health, Inc. Common Stock

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Wellgistics Health, Inc. is a wholesaler and distributor of pharmaceutical products to pharmaceutical manufacturers and independent retail pharmacies in the United States. The company is headquartered in Tampa, Florida.

Want to dig deeper into these stocks?